This study aimed to investigate the effect of polydatin against thrombosis and its possible mechanisms. The methods of injection of arachidonic acid into mouse tail vein electrically stimulated carotid thrombosis in rats, and the rats' inferior vena ligation were used to evaluate the antithrombotic effects of polydatin. Platelet aggregation was tested by use of Born's method, and platelet cytosolic calcium was determined by use of Fura-2/AM. Thromboxane B 2 and 6-keto-prostaglandin F 1 level was monitored by the immuno-assay, while Rosette assay and Born's method were used to observe plateletneutrophil interactions. The results show that polydatin had evident antithrombotic effects in the multiple-thrombosis models; the mechanisms may be closely related to its anti-platelet aggregation, which results in decrease of platelet cytosolic calcium and plasma thromboxane B 2 , while increasing plasma 6-keto-prostaglandin F 1 Level and suppressing of platelet-neutrophil interactions.
INTRODUCTION
Modern researches show that the process of thrombosis is closely related with interactions of platelets, leukocytes and other cells. Activated platelets can release some active substances including platelet activating factor (PAF) and thromboxane. Such active substances activate polymorphonuclear leukocytes (PMN), and activated PMNs accelerate the expression of platelet selectin so that adhesion between PMNs and platelets occurs while producing more thromboxane and promoting the mobilization of platelet intracellular calcium (Armstrong et al., 2008; Chlopicki et al., 2003) . Therefore, an obvious platelet aggregation is induced, which results in acceleration of the process of thrombosis eventually.
Thromboembolic diseases are great threats to human's life and health and prevention and treatment of thrombosis is a focus of modern medical research. One of the new hopes in this field of disease may be found in high effective drugs from natural products. Polydatin (3,4'-5-*Corresponding author. E-mail: shzhq21cn@yahoo.com.cn. Tel: +86 13888400622. Fax: +86 871 5426171. trihydroxystilbene-3-beta-D-glucopyranoside, Figure 1 ), a glucoside of resveratrol, is widely distributed in many plants especially in Polygonum cuspidatum and shows protective effects against hyperlipemia and ischemia/ reperfusion injury Zhang et al., 2008; Huang et al., 2003; Du et al., 2009 ). Hence, its pharmacological effects in cardiovascular fields are to attract broad attention in recent years.
Platelet hyperfunction and abnormality in thromboxane A 2 (TXA 2 ) and prostacyclin equilibrium is closely related to thrombosis and TXA 2 is a mediator of the sudden death induced by intravenous arachidonate in mice. AA, as a substrate of cyclooxygenase (COX), is transformed to two unstable intermediate products -prostaglandin G 2 (PGG 2 ) and prostaglandin H 2 (PGH 2 ). PGG 2 and PGH 2 can form TXA 2 through the action of thromboxane synthetase and an increase of TXA 2 will result in the adhesion, aggregation and release of platelets. PGG 2 and PGH 2 can also form prostacyclin I 2 (PGI 2 ) through the action of prostacyclin synthetase and the PGI 2 is able to inhibit platelet aggregation. Accordingly, drugs' inhibition on the metabolism of AA is likely to inhibit the activity of COX or affect the activities of thromboxane synthetase or prostacyclin synthetase (Gross and Moore, 2004) . The biological half-life of TXA 2 and PGI 2 are about 30 s and 3 min, respectively, then they turn into TXB 2 and 6-keto-PGF 1 rapidly. Thus, the determination of TXB 2 and 6keto-PGF 1 is used as a chief means of estimating the levels of TXA 2 and PGI 2 (Terashita et al., 1995) .
Electrical stimulation on rat carotid artery can injure vas endodermis, activates platelets and neutrophils, induce platelet aggregation and finally leads to a mixed thrombus. This experiment is to investigate antithrombotic effect of polydatin by the use of multiple arterial and venous thrombosis models and to explore its antithrombotic mechanisms by detecting the effects of polydatin on platelets, neutrophils, thromboxane B 2 (TXB 2 ), 6-ketoprostaglandin F 1 , and platelet cytosolic calcium, in view of providing more detailed bases for curing thrombotic diseases with polydatin.
MATERIALS AND METHODS

Drugs and reagent
The rhizomatic parts of P. cuspidatum were obtained in Yunnan Province of China. The plant was identified by Prof. Renwei Zhang (Yunnan Institute of Materia Medica) and a voucher specimen is deposited in the herbarium collection of the Institute (Yun. No. 025618). The medicinal materials were extracted with alcohol and the filtrates were extracted by ethyl acetate. The extracts were concentrated and separated on macroporous resin and Al2O3 column. High performance liquid chromatography (HPLC) was used for quantitative analysis of the obtained polydatin (molecular formula C20H22O8, molecular weight 390.40, purity 99%).
Polydatin was dissolved in 0.9% saline (pH 7.0) before use. Aspirin (Sigma) was dissolved with 100 mmol/L Na2CO3 before use, pH7.0. Arachidonic acid (AA) (Sigma) was dissolved in absolute alcohol and also diluted with 100 mmol/L Na2CO3. Adenosine diphosphate (ADP) (Fluka) was dissolved in 0.9% saline, pH 7.0. Platelet activating factor (PAF) (Sigma) was dissolved in Tris-NaCl buffer solution, which involved 0.25% bovine serum albumin (BSA), pH7.5. Thrombin (Sigma) was dissolved in 0.9% saline, pH 7.0. Nformyl-methionyl-leucyl-phenylalanine (fMLP) (Sigma) was dissolved in dimethyl sulfoxide and was diluted with distilled water before use. Fura-2/AM was from Sigma. The radioimmunoassay kits of TXB2 and 6-keto-PGF1 were purchased from ShenKe Biological Technology Co. LTD, Shanghai, China.
Animals
Healthy rabbits weighing 2.0 to 3.0 kg, male Sprague-Dawley (SD) rats weighing 250 to 300 g and male ICR mice weighing 22 to 26 g, were offered by the Experimental Animal Center of Yunnan Key Laboratory of Pharmacology for Natural Products. The protocol of this study was approved by the Ethics Committee of Kunming Medical University (SCXK2009008).
AA caused mouse' s death
Male ICR mice were randomly divided into 5 groups of 15 mice each. Group A: 0.9 % saline, group B: 10 mg/kg aspirin, and groups C to E: 5, 10 and 20 mg/kg polydatin. These 75 male ICR mice were no-eating overnight. Morrow, the mice were injected the above substances into tail veins. 0.5 h after administration, 80 mg/kg AA was intravenously injected into mice's tails at 50 µL / 10 g body weight. Myers's method was modified (Myers et al., 1986) . After 15 min, the number of surviving animals in the treatment and control groups was counted.
Electrically stimulated rat carotid artery thrombosis
SD rats were randomly divided into 5 groups of 10 rats each. Group A: 0.9% saline, group B: 10 mg/kg aspirin, and groups C to E: 5, 10, and 20 mg/kg polydatin respectively. The rats were anaesthetized by 30 mg/kg of sodium amobarbital, and were injected in femoral vein with the aforementioned substance. 15 min after administration, Charlton's method was modified (Charlton et al., 1996) . The artery was electrically stimulated (1.5 mA for 7 min) using an electronic stimulator (model SEN-7203, Nihon Kohden Corporation, Japan). The time to the formation of an occlusive thrombus (zero arterial flow) was recorded with a Direction Volume Meter (model DVM-4200, Hayashi Denki Corporation, Japan). If the vessels were still patent at the end of this observation period, the duration of 60 min was ascribed to allow statistical analysis of the data.
Ligated rat inferior vena cava thrombosis
The rats were randomly divided into 5 groups of 10 rats each. Group A: 0.9% saline, group B: 10 mg/kg aspirin and groups C to E: 5, 10 and 20 mg/kg polydatin respectively. The rats were anaesthetized by 30 mg/kg of sodium amobarbital. Vein thrombosis model were duplicated according to the method described by CX Chen (Chen et al., 1992) . The rat's abdomen was opened and the inferior vena cava was isolated and ligated below the left renal vein level, and then the abdomen was closed. After 1 h, the rats were injected in femoral vein with the above substance in a volume of 0.1 mL/ 100 g body weight, respectively. Two hours later, the abdomen was reopened. The thrombus in the inferior vena cava was collected into a glass dish for measurement of wet weight. It was then placed in a drying oven at 60°C for 20 h before measuring the dry weight.
Preparation of platelet (Shen et al., 2003)
Healthy rabbits were used. Blood from rabbit's carotid artery was mixed with one-sixth volume of acid citrate dextrose (sodium citrate 25, citric acid 15, and D-glucose 20 g/L, for the measurement of platelet cytosolic calcium level). This blood was then spun to obtain platelet-rich plasma (PRP) at 300 × g for 15 min. PRP was further spun at 1000 × g for 10 min to pellet the platelets. Platelet pellets were gently suspended in prewarmed Tyrode-HEPES buffer (containing NaCl 134, KCl 2.9, NaHCO3 12, NaH2PO4 0.36, MgCl2 1, glucose 5, HEPES 5 mmol/L and bovine serum albumin 0.35%, pH 7.2). After washed twice, the cells were resuspended in the above buffer solution. The platelet count was adjusted to about 5 × 10 8 cell / L.
Blood from rabbit carotid artery was collected into plastic tubes, anticoagulated with 2.7% of ethylenediaminetetraacetic acid (EDTA) (for the binding of platelets to neutrophils) or 3.8% sodium citrate acid (for aggregation). This sample was spun for 10 min at 180 × g to obtain PRP. PRP was further spun to pellet platelets at 1000 × g for 10 min. Platelet pellets were washed three times and resuspended in phosphate buffer solution (PBS, containing 1.0% bovine serum albumin, 1.4 mmol/L EDTA, and 1 mmol/L CaCl2). Cell viability by Typan blue exclusion was above 95 % and cell counter was adjusted to 10 8 cell/mL.
Preparation of neutrophils (Shen et al., 2003)
Neutrophils were isolated from the blood (coagulated by 2.7% edetic acid, from which platelet-rich plasma was removed). The cell pellet was resuspended in an erythrocyte lysis buffer composed of 155 mmol/L NH4Cl, 2.96 mmol/L KHCO3, and 3.72 mmol/L acetic acid. The tube was gently inverted, then after 5 min the suspension was centrifuged at 350 × g for 10 min, and the cell pellet was washed in PBS lacking calcium; then resuspended in Hanks' solution (containing 1 mmol/L CaCl2 or 5 mmol/L egtazic acid in vehicle, reflecting the situation with or without external calcium). Cells were adjusted to a count of 2 × 10 8 cell/mL (for adhesion) or 0.5 ×10 6 cell/mL (for platelet aggregation). Cells prepared in this manner contained 98% neutrophils and were 96% viable.
Platelet aggregation in vitro
Platelets aggregation was determined by Born's methods (Born, 1962) . PRP was further spun at 3000 × g for 15 min to obtain platelet-poor plasma (PPP). The maximal aggregation was monitored in a Lumiaggregometer (Kemao Limited Company, Beijing, China). The final concentrations of ADP, AA and PAF were 3 µmol/L, 0.35 mmol/L and 7.2 nmol/L, respectively. Percentage inhibition by drugs was calculated by use of the following equation:
Inhibition of aggregation (%) = (A -B) / A ×100
Where, A is the maximum change of turbidity when the control (saline) is added and B is the maximum change of turbidity when the drug (different concentrations of polydatin or aspirin) is added.
Platelet aggregation ex vivo
The animals were randomly divided into 5 groups of 6 rabbits. Chen et al. 14179 Group A: 0.9% saline, group B: 10 mg/kg aspirin and groups C to E: 5, 10, and 20 mg/kg polydatin respectively. Blood sample from rabbit carotid artery was collected before administration. PRP and PPP were prepared before administration and at 0.5, 1, 1.5, 2, 3 and 4 h after administration, respectively. Platelet aggregation induced by ADP, AA or PAF was monitored as the in vitro test, respectively.
Platelet cytosolic calcium level
Intracellular Ca 2+ concentration of platelets was measured by using Fura-2-AM with a spectrofluorophotometer (Model RF-5000, Shimazhu, Japan) at 37°C and magnetically stirred. The cells were treated with 0.1% Triton X-100 followed by the addition of egtazic acid 10 mmol/L to obtain the maximal and minimal fluorescence, respectively. The ratio of the measured fluorescence values at 340 and 380 nm excitation was calculated. [Ca 2+ ]i was calculated by the method of Grynkiewicz G (Grynkiewicz et al., 1985) . AA (200 µmol/L)-induced rise in [Ca 2+ ]i was measured in the presence of 1 mmol/L CaCl2 or 1 mmol/L egtazic acid, respectively.
Determination of TXB2 and 6-keto-PGF1
Before injection and at 30, 60, 120 min after injection of the drugs, rabbit blood from carotid artery was anticoagulated with heparin (3.5 mg/mL) and spun at 1000 × g at 0°C for 10 min to obtain plasma. TXB2 and 6-keto-PGF1 in plasma were extracted from the supernatant and assayed by use of radioimmunoassay kits.
Rosette assay (Shen et al., 2004)
The method of Rosette assay was modified. 50 µL of platelets and 0.2 U/mL thrombin were mixed and incubated for 15 min at 37°C, 50 µL of drugs were then added and incubated for another 15 min. Then 100 µL of neutrophils was added to the platelet suspension. One hundred neutrophils were scored for the presence (two or more platelets per neutrophil) or absence (zero or one platelet per neutrophil) of platelets. Neutrophils bearing two or more platelets were thus defined as rosettes. For each assay done in triplicate, the rosetting score was assessed by two different observers.
Inhibition of platelet aggregation induced by the suspension of activated neutrophils
100 µL of platelets (10 8 cell/mL) were mixed with 100 µL of neutrophils (0.5 ×10 7 cell/mL) and stirred for 2 min at 37°C. 0.9% saline or drug solution was added and incubated for 5 min and then 2 µmol/L of fMLP was added. Platelet aggregation was observed using the earlier described method (Born, 1962) .
Statistical analysis
The data were analyzed by the software bag of SPSS (Version 13, SPSS Inc., USA). All enumeration data were expressed as percentages and analyzed by use of Chi-square test. All measurement data were expressed as mean ± SD, and analyzed by one way ANOVA and least-significant difference (LSD) test, respectively. Differences were considered statistically significant when P < 0.05. Values are means ± SD, n = 10, ** P < 0.01, compared with saline. All the substances were administered intragastrically. 15 min after administration, the carotid artery was electrically stimulated at 1.5 mA for 7 min. The experiment was terminated 60 min after stimulation.
RESULTS
Preventive effect of polydatin against mouse sudden death caused by injection of AA
Polydatin at 5, 10 and 20 mg/kg had a potent inhibitory effect on mouse death as a result of pulmonary thrombi induced by AA injection into the tail vein (Table 1) .
Effect of polydatin on electrically stimulated arterial thrombosis in rats
Polydatin at 5, 10 and 20 mg/kg significantly prolonged the occlusion time in a dose-dependent manner. The reference compound aspirin also delayed the occlusion time ( Table 2) .
Effect of polydatin on inferior venous thrombosis in rats
In saline group, the wet and dry thrombus weights were 10.3 ± 1.6 and 4.8 ± 0.8 mg, respectively. Polydatin at 5, 10 and 20 mg/kg evidently reduced the wet and dry thrombus weight (Table 3) .
Effects of polydatin on rabbit platelet aggregation in vitro
Polydatin concentration-dependently suppressed platelet aggregation induced by AA and ADP, but not by PAF. The IC 50 values were 5.13 for AA and 10.07 µmol/L for ADP, respectively ( Table 4 ).
Effects of polydatin on rabbit platelet aggregation ex vivo
Polydatin at 5, 10 and 20 mg/kg also showed potent inhibitory effects on AA or ADP-induced platelet aggregation, but had no inhibitory effect on PAF-induced platelet aggregation (Table 5) .
Effect of polydatin on platelet cytosolic calcium level
In the presence of 1 mmol/L CaCl 2 , the resting cytosolic 1.3 ± 0.5**
Values are means ± SD, n = 10, ** P < 0.01, compared with saline. The inferior vena cava was isolated and ligated below the left renal vein level. 1 h after ligation, the substances were administered through the femoral vein in a volume of 0.1 mL/100 g body weight, respectively. 2 h later, the thrombus in the inferior vena cava was collected into a glass dish for measurement of wet weight. It was then placed in a drying oven at 60°C for 20 h before measuring the dry weight. 63.8 ± 8.9** 42.8 ± 4.8** 1.5 ± 0.9 18.8 73.2 ± 6.9** 59.8 ± 6.7** 1.5 ± 1.0 37.5 90.3 ± 2.0** 79.8 ± 5.6** 2.0 ± 0.9 75 93.7 ± 2.9** 87.0 ± 4.1** 2.3 ± 1.2 150 96.3 ± 1.6** 85.3 ± 5.2** 1.8 ± 1.5
Aspirin 37.5 55.5 ± 2.9** 1.4 ± 0.9 1.6 ± 1.1 75 70.3 ± 4.0** 2.1 ± 1.2 1.9 ± 1.5 150 96.5 ± 3.9** 1.8 ± 0. (Table 6 ).
Effect of polydatin on rabbit plasma levels of TXB 2 and 6-keto-PGF 1
Polydatin at 5, 10 and 20 mg/kg significantly decreased plasma TXB 2 level and increased plasma 6-ketoprostaglandin F 1 level. Aspirin strongly decreased the levels of both TXB 2 and plasma 6-keto-prostaglandin F 1 in plasma (Tables 7 and 8) .
Effect of polydatin on the binding of thrombinactivated platelets to neutrophils
The percentage of rosettes in saline group was 69.7 or 13.3% in a condition of external 1 mmol / L CaCl 2 or 5 mmol/L egtazic acid. Polydatin and aspirin significantly decreased the binding of platelets to neutrophils with 1 mmol/L external Ca 2+ . The IC 50 values were 51.9 and 61.8 µmol/L, respectively (Table 9 ).
Effect of polydatin on platelet aggregation induced by the suspension of activated neutrophils
Polydatin markedly inhibited platelet aggregation induced 67.2 ± 4.2** 89.7 ± 2.9** 88.2 ± 6.8** 65.5 ± 4.2** 58.8 ± 4.6** 50.8 ± 6.4** 20 71.5 ± 4.6** 92.2 ± 2.6** 93.2 ± 2.4** 71.8 ± 6.9** 60.5 ± 3.7** 49.0 ± 6.4** Aspirin 10 54.8 ± 8.7** 72.2 ± 9.7** 84.2 ± 6.6** 90.5 ± 4.3** 72.5 ± 7.2** 68.8 ± 6.1** ADP Polydatin 5 51.3 ± 2.1** 67.3 ± 6.1** 64.0 ± 7.9** 51.3 ± 8.4** 40.2 ± 3.7** 37.5 ± 5.0** 10 56.7 ± 3.3** 77.3 ± 2.6** 74.5 ± 5.2** 57.3 ± 5.9** 48.8 ± 3.2** 41.7 ± 6.8** 20 65.3 ± 5.3** 79.5 ± 7.4** 70.3 ± 3.8** 62.5 ± 7.2** 53.7 ± 6.1** 45.0 ± 10.1** Aspirin 10 7.7 ± 2.2 11.3 ± 3.3 14.8 ± 3.1 16.5 ± 4.9 12.7 ± 3.3 11.5 ± 3.9 PAF Polydatin 5 10.0 ± 2.9 8.3 ± 3.1 9.5 ± 1.9 8.5 ± 2.6 7.7 ± 2.2 6.5 ± 1.9 10 11.8 ± 2.5 9.7 ± 2.5 9.2 ± 3.4 11.5 ± 4.0 8.2 ± 2.8 7.0 ± 1.4 20 11.5 ± 2.7 12.2 ± 4.0 10.7 ± 3.1 9.7 ± 2.0 7.2 ± 2.6 5.5 ± 1.9
Aspirin 10 1.8 ± 1.2 3.8 ± 1.5 4.8 ± 2.1 6.2 ± 2.8 4.5 ± 1.9 4.2 ± 2.4
Values are means ± SD, n = 6, *P < 0.05, **P < 0.01, compared with 0 min. Platelet aggregation rate at 0 min (%): AA 73.7 ± 5.6, ADP 64.3 ± 4.6 and PAF 58.2 ± 5.3. by the suspension of fMLP-activated neutrophils. The IC 50 was 307.6 µmmol/L (Table 10) .
DISCUSSION
Injection of AA caused platelet aggregation in lung, a lesser circulation and brought about a decline in the breath and blood circulation which eventually induce sanimal's death De Leval et al., 2004) . Polydatin obviously reduced the mortality of mice in this model. It is suggested that polydatin showed potent inhibition on the activity of AA and TXA 2 . Electrical stimulation thrombosis model is similar to human artery thrombosis and has little determinate error (Schumacher et al., 1996) . Polydatin at 5 mg/kg could significantly prolong the occlusion time. It is suggested that polydatin showed the activity of anti-artery thrombosis.
In rat inferior vena ligation model, polydatin at 5, 10 and 20 mg/kg evidently reduced the wet and dry thrombus weight. It is suggested that polydatin prevented against the formation of venous thrombosis. In these thrombotic models, polydatin showed dose-dependently antithrombotic effects. To confirm its possible mechanisms, a Values are means ± SD, n = 6, *P < 0.05, **P < 0.01, compared with saline. Values are means ± SD, n = 6, *P < 0.05, **P < 0.01, compared with saline. Values are means ± SD, n = 6, *P < 0.05, **P < 0.01, compared with saline. The percentage of saline group was 69.7 in a condition of external 1 mmol/L CaCl2. 29.3 ± 6.9** 64.5 ± 7.5
Values are means ± SD, n = 10, *P < 0.05, **P < 0.01, compared with the platelet aggregation rate before drugs were added.
series of studies were conducted. Activation and aggregation of platelets is an important reason in the process of thrombosis. Multiple pathways contribute to platelet activation and AA, ADP and PAF are considered as the main activating agents in this process (Vargaftig et al., 1980) . This study confirms that polydatin significantly inhibited AA-and ADP-induced platelet aggregation in vitro and ex vivo. It is suggested that polydatin may selectively affect ADP receptors and cyclooxygenase pathway, but do not act on PAF receptors. These results indicate that the antithrombotic effects of polydatin may be related with its antiplatelet aggregation. Activation of blood platelets (including aggregation and release) occurs always through an elevation of [Ca 2+ ] i (Nesbitt et al., 2003) . Influence of polydatin on the increase of [Ca 2+ ] i stimulated by AA was measured in this investigation. The AA-induced [Ca 2+ ] i increase in the presence of CaCl 2 was more than that in the absence of extracellular Ca 2+ , suggesting that the major component of the AA-induced increase in [Ca 2+ ] i is caused by the influx of Ca 2+ ions across the plasma membrane. Polydatin concentration-dependently lowered the [Ca 2+ ] i increase stimulated by AA in the presence of CaCl 2 or EGTA, respectively. This demonstrated that polydatin inhibited both the influx of extracellular calcium and the mobilization of calcium from intracellular stores.
This study shows that polydatin significantly elevated plasma level of 6-keto-PGF 1 while markedly reducing that of TXB 2 . It is suggested that the mechanism of polydatin on inhibiting the metabolism of AA do not be restrain of the activity of COX, but due to its modulation on PG I 2 an d T X A 2 . AA can cause rapid formation of TXA 2 in platelets and TXA 2 can stimulate [Ca 2+ ] i level and result in platelet aggregation. Polydatin at the dose range that inhibited platelet aggregation and TXB 2 formation, could significantly suppress [Ca 2+ ] i increase stimulated by AA. It is suggested that the antiplatelet effect of polydatin may be due to its ability to inhibit Ca 2+ elevation. P ol yd a t i n, t h er ef or e, is different from aspirin both in potency and quality of antiplatelet and antithrombosis.
Neutrophils and platelets, but not platelets alone, are closely associated with thromboembolic disorders. Interactions of these two kinds of blood cells are involved in the process of thrombomodulation (Zhao et al., 2008) . Platelet-derived products are able to promote neutrophil chemotaxsis, enzyme release and phagocytosis, and to inhibit oxidative burst. On the other hand, neutrophilderived products can enhance platelet aggregation (Caron et al., 2002) . Thus, it is more advantageous to develop an antithrombotic drug especially at an angle of influencing multiple cellular interactions. Thrombus formation is mediated by the platelet-neutrophil interactions including cell binding and platelet aggregation (Wetterö et al., 2003) . Clinical studies showed that platelet-neutrophil rosette in patients with thrombotic disease significantly increased (Papalambros et al., 2004) . Polydatin showed significant inhibition on rosetting between thrombin-activated platelets and neutrophils. Polydatin also exerted a concentration-dependent inhibitory effect on platelet aggregation induced by the supernatant from fMLP-activated neutrophils. It is suggested that polydatin showed potent antithrombotic activity also due to its influence on platelet-neutrophil interactions. Taken together, these results suggest that polydatin has the potential to become a useful antiplatelet and antithrombotic drug.
